Atomwise Inc. (Atomwise), formerly known as Chematria Inc., develops AI systems using deep learning algorithms to discover and develop new drugs and agricultural compounds. Atomwise introduced AtomNet, a deep learning neural network, which predicts the bioactivity of small molecules used for drug discovery. The company has partnerships with agrochemical and pharmaceutical firms, hospitals, and academic institutions for advancing research activities in subjects like leukemia, ebola, multiple sclerosis, nematicides, and fungicides leveraging its competencies in AI. Bayer, Charles River Laboratories, University of Toronto, Merck, Abbvie, Hansoh Pharma, and SEngine Precision Medicine are some major partners. Atomwise introduced Artificial Intelligence Molecular Screen (AIMS) awards program, which supports and encourages researchers at academic research institutions, universities, and hospitals across the globe to develop new drugs.
The report provides information and insights into Atomwise's, including:
- Overview of the company and its product offering
- Detailed insight into its business model, company type and headquarter
- Information on funding and partnership
- Biography of top management
Reasons to Buy
- Gain insights into Atomwise's business operations.
- Gain insights into partnership and funding.
- Gain understanding about its technology focus.
Table of Contents
- Company Overview
- Technology Focus
- Product Overview
- Partnership
- Funding
- Key Employees
- Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer
- Atropos Therapeutics
- Hansoh Pharmaceutical
- Monsanto
- Michigan Medicine
